One Hotel Drive,

Boston,

MA,

US,

ZIP: 02128

Phone: +16174554188

Over the last 12 months, the industry has witnessed promising data and candidates entering the clinic. 7 Hills Pharma, Corbus Pharmaceuticals, Vincerx, and Morphic are paving the way to develop a safe, efficacious integrins-targeted drug to modify disease biology, which will be a game-changer for diseases such as oncology, autoimmune, and ophthalmology, with unmet medical needs.

In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success, including patient selection biomarkers and dosing.

Get your critical questions answered to supercharge your clinical programs, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic, familiar, and rare diseases.

Join us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients.


URLs:
Tickets: https://go.evvnt.com/1173725-2?pid=1052
Brochure: https://go.evvnt.com/1173725-3?pid=1052

Prices:
Drug Developer - Conference + Focus Day: USD 4796.00,
Drug Developer - Conference Only: USD 2999.00,
Academic and Start Ups - Conference + Focus Day: USD 4096.00,
Academic and Start Ups - Conference Only: USD 2599.00,
Service Provider - Conference + Focus Day: USD 5696.00,
Service Provider - Conference Only: USD 3599.00

Bernhard Wehrle-Haller, Professor, Geneva University, Bruce Rogers, President, Morphic Therapeutics, Darren G. Woodside, Vice President of Research, Texas Heart Institute, Dermot Cox, Associate Professor Pharmacy and Biomolecular Sciences, Royal College of Surgeons, Ireland, Eric Lefevbre, Chief Medical Officer, Pliant Therapeutics, Evy LundgrenAkerlund, Chief Executive Officer, Xintela, Gregory Bix, Professor, Tulane University, Horst Kessler, Professor, Technical University Munich, Kevin Hart, Senior Principal Scientist, Pfizer, Per Norlén, Chief Executive Officer, Targinta, Peter Vanderslice, Co-Founder, 7 Hills Pharma, Riccardo Canevari, Chief Executive Officer, Radiopharm Theranostics, Scott Edwards, Chief Development Officer, OcuTerra, Scott Turner, Senior Vice President of Research, Pliant Therapeutics, Shaker Mousa, Professor and Chairman, Founder and Executive Vice President, Albany College, NanoPharmaceuticals, Stephen Nishimura, Professor, UCSF, Tangsheng Yi, Director, Inflammation/ Immunology, Gilead